Vivek Tanavde is an expert in Biochemistry at Ahmedabad University (India). Vivek Tanavde has authored 48 publications, the most recent in 2024. SLR score: 136 (community average: 125). How the SLR is computed.

LeadR Profile

Vivek Tanavde Ahmedabad University India
136 ScienceLeadR Reputation 136
Network Map

Biochemistry

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2024
Source: PubMed

Agency for Science, Technology and Research

2012 - 2024

Ahmedabad University - Associate Professor

2016 - 2024

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 48

Citations

Citations: 2 664 1st author: 4 Last author: 12 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells.
PMID 39730440 — cells, paclitaxel, pharmaceutical preparations, ovary, antineoplastic agents, neoplasms, ovarian neoplasms, natural science disciplines, therapeutics, rosiglitazone, apoptosis, cell cycle
Sci Rep20244
Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: Therapeutic implications, effective strategies and approaches.
PMID 38353369 — drug resistance, plants, medicinal, pharmaceutical preparations, stem cells, therapeutics, neoplasms, microscopy, electron, scanning transmission, biological availability, silybin
Phytother Res20241
Correction: A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma.
PMID 38409134 — cells, carcinoma, squamous cell, micrornas
Biomark Res20241
A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma.
PMID 37316916 — cells, cell proliferation, carcinoma, squamous cell, micrornas, disease progression, biomarkers, exosomes, cell line, diagnosis, apoptosis, cell cycle
Biomark Res202321
Salinomycin mediated therapeutic targeting of circulating stem like cell population in oral cancer.
PMID 34308783 — cell cycle, molecular biology, therapeutics, microscopy, electron, scanning transmission, mouth neoplasms, neoplastic cells, circulating, real-time polymerase chain reaction
J Biomol Struct Dyn20211

LeadR Networks

Main global connection map